Yanofsky Theresa sold $14K of CGC

Yanofsky Theresa sold 14,920 shares of Canopy Growth Corp (CGC) at $0.93 on 2026-09-28.

Original reporting
SEC EDGAR · Yanofsky Theresa
Published Sep 30, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Bearish
high confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCBearishLow
01

Why it matters

The director's sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: post-market filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$CGCBearishHigh confidence
Context

Director Theresa Yanofsky sold 14,920 shares for $13,828 on Sep 28, 2026, reducing her stake to 131,495 shares.

Expected impact

likely pressure as market prices in the insider sale

Evidence & confidence

The sale is small but signals potential lack of confidence from a director.

Market effects

Limited impact on cannabis sector; typical insider transaction.

No broader regional effect.

Minimal.

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Canopy Growth Corp

    Canadian cannabis producer listed on NYSE under ticker CGC.

  • Theresa Yanofsky

    Director of Canopy Growth Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.